Zura Bio (NASDAQ:ZURA) Announces Earnings Results

Zura Bio (NASDAQ:ZURA) issued its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02, FiscalAI reports.

Zura Bio Stock Up 6.0%

Shares of ZURA opened at $3.56 on Tuesday. The stock has a market cap of $341.15 million, a price-to-earnings ratio of -3.15 and a beta of 0.01. Zura Bio has a 12 month low of $3.25 and a 12 month high of $7.44. The company has a 50-day moving average price of $4.79 and a two-hundred day moving average price of $5.26.

Institutional Investors Weigh In On Zura Bio

Large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its position in shares of Zura Bio by 83.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 43,135 shares of the company’s stock worth $257,000 after buying an additional 19,603 shares during the period. Bank of America Corp DE lifted its holdings in Zura Bio by 3,007.7% during the 1st quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock valued at $812,000 after purchasing an additional 132,130 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Zura Bio by 3.4% during the 1st quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock valued at $1,864,000 after purchasing an additional 10,200 shares during the last quarter. ADAR1 Capital Management LLC boosted its position in Zura Bio by 12.2% in the first quarter. ADAR1 Capital Management LLC now owns 630,403 shares of the company’s stock valued at $3,751,000 after buying an additional 68,338 shares in the last quarter. Finally, Stempoint Capital LP bought a new stake in Zura Bio during the first quarter worth about $4,483,000. 61.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZURA has been the subject of a number of research analyst reports. William Blair assumed coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating for the company. Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Wedbush boosted their price target on Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Guggenheim boosted their price target on Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Zura Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

About Zura Bio

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.